Skip to content
value.today
Achieve Life Sciences, Inc. logo

Achieve Life Sciences, Inc.

ACHV
$791 Mmarket cap on Oct 30, 2026+799.0% since Jan 2024
Compare
World rank
#10,435
Revenue
—
For year ending December-2025
Net income
$-55 M
SEC filing
Employees
28
As of December 31, 2025
SEC filing

Achieve Life Sciences, Inc. in brief

Achieve Life Sciences, Inc. is a listed company in the Biotechnology industry, based in Seattle, Washington, USA. Its market value was $791 M on 30 October 2026, which makes it the 10,435th largest listed company in the world and the 2,207th largest in the USA on this site. It employs about 28 people and Andrew D. Goldberg is its chief executive. Its shares trade under the symbol ACHV (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Achieve Life Sciences, Inc.

We are a late-stage clinical specialty pharmaceutical company with the sole mission to address the global nicotine dependence epidemic through the development and commercialization of cytisinicline. There are an estimated 29 million adults in the United States alone who smoke combustible cigarettes and an estimated 17 million adults in the United States who utilize e-cigarettes. Tobacco use is currently the leading cause of preventable death and is responsible for more than eight million deaths worldwide and nearly half a million deaths in the United States annually. More than 87% of lung cancer deaths, 61% of all pulmonary disease deaths, and 32% of all deaths from coronary heart disease are attributable to smoking and exposure to secondhand smoke. Our primary focus is to address this global epidemic.

From the company's annual report filed with the US SEC: read the report

Achieve Life Sciences, Inc. timeline

3 events, 1996–2017
  1. 1996
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2008
  4. ✎
    Renamed Oncogenex Pharmaceuticals, Inc.
    Formerly Sonus Pharmaceuticals Inc.
  5. 2017
  6. ✎
    Renamed Achieve Life Sciences, Inc.
    Formerly Oncogenex Pharmaceuticals, Inc..

Events of Achieve Life Sciences, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$214 M$427 M$641 M$854 M2023202420252026

World rank over time

▲ up 13,848 places since 2022
2022-01-07: #24308#24,30820222022-12-25: #25690#25,69020222023-07-30: #20824#20,82420232024-01-05: #22090#22,09020242026-03-08: #8807#8,80720262026-08-01: #10369#10,36920262026-10-14: #10636#10,63620262026-10-30: #10460#10,4602026

Rank in USA: #4,616 (Jan 2022) · #4,864 (Dec 2022) · #4,067 (Jul 2023) · #3,784 (Jan 2024) · #1,649 (Mar 2026) · #2,249 (Aug 2026) · #2,243 (Oct 2026) · #2,208 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
36.8×
Free cash flow yield
-6.3%
Net margin
—
Operating margin
—
Return on equity
-253.9%
Liabilities / assets
48.5%
Profit per employee
$-2.0 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue —, net income $-13M—FY18Fiscal year ending Dec 2019: revenue —, net income $-16M—FY19Fiscal year ending Dec 2020: revenue —, net income $-15M—FY20Fiscal year ending Dec 2021: revenue —, net income $-33M—FY21Fiscal year ending Dec 2022: revenue —, net income $-42M—FY22Fiscal year ending Dec 2023: revenue —, net income $-30M—FY23Fiscal year ending Dec 2024: revenue —, net income $-40M—FY24Fiscal year ending Dec 2025: revenue —, net income $-55M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025———$-55M—
Dec 2024———$-40M—
Dec 2023———$-30M—
Dec 2022———$-42M—
Dec 2021———$-33M—
Dec 2020———$-15M—
Dec 2019———$-16M—
Dec 2018———$-13M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-49M$0M$-49M$-1.25—
Dec 2024$-30M——$-1.24—
Dec 2023$-24M$0M$-25M$-1.50—
Dec 2022$-38M——$-4.00—
Dec 2021$-29M——$-4.08—
Dec 2020$-13M$0M$-13M$-5.42—
Dec 2019$-15M$0M$-15M$-39.76—
Dec 2018$-11M$0M$-11M$-72.29—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-12M—Dec ’24Three months to Mar 2025: revenue —, net income $-13M—Mar ’25Three months to Jun 2025: revenue —, net income $-13M—Jun ’25Three months to Sep 2025: revenue —, net income $-14M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-15M—Dec ’25Three months to Mar 2026: revenue —, net income $-10M—Mar ’26Three months to Jun 2026: revenue —, net income $-75M—Jun ’26Three months to Sep 2026: revenue —, net income $-12M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-12M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Achieve Life Sciences, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
—
Net income
$-55 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$42 M
Total liabilities
$20 M
Total equity
$22 M

As of December-2025

Top 100 institutional investors in Achieve Life Sciences, Inc.#

As of Sep 30, 2026
132 institutions held 95.2 M shares (about 86.5% of the shares outstanding) on Sep 30, 2026. The ten largest hold 46.8%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Achieve Life Sciences, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Frazier Life Sciences Management, L.P.7,614,8360 (0.00%)6.92%$62 MNov 16, 2026
2TPG GP A, LLC6,877,5800 (0.00%)6.25%$56 MNov 16, 2026
3venBio Partners LLC5,914,7200 (0.00%)5.38%$48 MNov 16, 2026
4Venrock Adviser, LLC5,502,064+2,751,032 (+100.00%)5.00%$45 MNov 16, 2026
5BlackRock, Inc.5,487,278+215,261 (+4.08%)4.99%$44 MNov 13, 2026
6Paradigm Biocapital Advisors LP4,951,8560 (0.00%)4.50%$40 MNov 16, 2026
7Propel Bio Management, LLC3,864,148-169,870 (-4.21%)3.51%$31 MNov 13, 2026
8Jpmorgan Chase & Co3,788,388+3,756,099 (+11632.75%)3.44%$31 MNov 12, 2026
9Marshall Wace, LLP3,770,3130 (0.00%)3.43%$31 MNov 13, 2026
10State Street Corp3,718,240+772,714 (+26.23%)3.38%$30 MNov 12, 2026
11Eventide Asset Management, LLC3,571,721+1,351,721 (+60.89%)3.25%$29 MNov 13, 2026
12Vanguard Capital Management LLC3,480,234-660,578 (-15.95%)3.16%$28 MNov 13, 2026
13Logos Global Management LP3,200,000-2,225,000 (-41.01%)2.91%$26 MNov 16, 2026
14Franklin Templeton Inc3,130,950-1,822,270 (-36.79%)2.85%$25 MNov 12, 2026
15Janus Henderson Group Ltd.2,751,032—2.50%$22 MNov 16, 2026
16Vivo Capital, LLC2,751,0320 (0.00%)2.50%$22 MNov 13, 2026
17Orbimed Advisors LLC2,344,200New2.13%$19 MNov 16, 2026
18Geode Capital Management, LLC2,156,709+93,988 (+4.56%)1.96%$17 MNov 6, 2026
19Boxer Capital Management, LLC2,150,000New1.95%$17 MNov 16, 2026
20Wellington Management Group LLP1,648,859+221,944 (+15.55%)1.50%$13 MNov 16, 2026
21Alyeska Investment Group, L.P.975,722-950,000 (-49.33%)0.89%$8 MNov 16, 2026
22LPL Financial LLC973,585+71,330 (+7.91%)0.88%$8 MNov 6, 2026
23Simplify Asset Management Inc.932,105-500,000 (-34.91%)0.85%$8 MOct 27, 2026
24Bank of New York Mellon Corp753,900+535,774 (+245.63%)0.69%$6 MNov 5, 2026
25Northern Trust Corp743,368-392 (-0.05%)0.68%$6 MNov 16, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Achieve Life Sciences, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Spruce Street Capital LP736,6370 (0.00%)0.67%$6 MNov 13, 2026
27Vanguard Portfolio Management LLC735,325+197,729 (+36.78%)0.67%$6 MNov 13, 2026
28Ameriprise Financial Inc731,188New0.66%$6 MNov 16, 2026
29Vanguard Fiduciary Trust Co620,907+27,156 (+4.57%)0.56%$5 MNov 13, 2026
30Raymond James Financial Inc583,491+37,173 (+6.80%)0.53%$5 MNov 12, 2026
31Mercer Global Advisors Inc /adv550,551New0.50%$4 MNov 16, 2026
32ADAR1 Capital Management, LLC508,199+454,399 (+844.61%)0.46%$4 MNov 16, 2026
33KVP Capital Advisors, LP462,3550 (0.00%)0.42%$4 MNov 16, 2026
34Adage Capital Partners GP, L.L.C.460,000New0.42%$4 MNov 16, 2026
35Caption Management, LLC429,294+201,561 (+88.51%)0.39%$3 MNov 16, 2026
36Blue Owl Capital Holdings LP412,654New0.38%$3 MNov 13, 2026
37Point72 Asset Management, L.P.376,704New0.34%$3 MNov 16, 2026
38FMR LLC338,850+321,143 (+1813.65%)0.31%$3 MNov 10, 2026
39Renaissance Technologies LLC317,183+139,134 (+78.14%)0.29%$3 MNov 12, 2026
40UBS Group AG292,583-20,421 (-6.52%)0.27%$2 MNov 10, 2026
41Citadel Advisors LLC274,826+151,697 (+123.20%)0.25%$2 MNov 16, 2026
42Invesco Ltd.235,387+193,095 (+456.58%)0.21%$2 MNov 12, 2026
43Charles Schwab Investment Management Inc232,1380 (0.00%)0.21%$2 MNov 16, 2026
44Bank Of America Corp /de/212,754+27,679 (+14.96%)0.19%$2 MNov 16, 2026
45Morgan Stanley207,716+148,342 (+249.84%)0.19%$2 MNov 13, 2026
46Nuveen, LLC182,510-8,640 (-4.52%)0.17%$1 MNov 10, 2026
47Silverarc Capital Management, LLC158,950-68,228 (-30.03%)0.14%$1 MNov 12, 2026
48Goldman Sachs Group Inc155,598+114,622 (+279.73%)0.14%$1 MNov 16, 2026
49Informed Momentum Co LLC147,269New0.13%$1 MNov 16, 2026
50Hurricane Capital Advisors LLC137,550+102,550 (+293.00%)0.13%$1 MNov 16, 2026
51Cantor Fitzgerald, L. P.121,876-121,386 (-49.90%)0.11%$1 MNov 16, 2026
52Greenland Capital Management LP120,000New0.11%$1 MNov 16, 2026
53Wells Fargo & Company/mn119,232-51,401 (-30.12%)0.11%$1 MNov 16, 2026
54SEI Investments Co109,350+88,850 (+433.41%)0.10%$1 MNov 10, 2026
55Squarepoint Ops LLC102,572New0.09%$1 MNov 9, 2026
56Rafferty Asset Management, LLC90,967+53,446 (+142.44%)0.08%$1 MNov 13, 2026
57Rhumbline Advisers89,921+2,898 (+3.33%)0.08%$1 MNov 10, 2026
58Blue Trust, Inc.85,8880 (0.00%)0.08%$1 MOct 15, 2026
59Two Sigma Investments, LP81,648-359,539 (-81.49%)0.07%$1 MNov 16, 2026
60Engineers Gate Manager LP79,004New0.07%$1 MNov 16, 2026
61Polen Capital Management LLC78,146New0.07%$1 MNov 13, 2026
62Prospera Financial Services Inc74,550New0.07%$1 MNov 4, 2026
63Shay Capital LLC71,853-20,957 (-22.58%)0.07%$1 MNov 16, 2026
64Deutsche Bank AG\67,558-9,927 (-12.81%)0.06%$1 MNov 6, 2026
65Manchester Financial Inc67,1770 (0.00%)0.06%$1 MOct 15, 2026
66Members Wealth LLC66,7630 (0.00%)0.06%$1 MOct 20, 2026
67Price T Rowe Associates Inc /MD/64,7690 (0.00%)0.06%$1 MNov 16, 2026
68WINTON GROUP Ltd58,800+16,300 (+38.35%)0.05%$0 MNov 12, 2026
69Virtus Investment Advisers, LLC57,488-1,787 (-3.01%)0.05%$0 MNov 12, 2026
70Vanguard Global Advisers, LLC56,745+24,337 (+75.10%)0.05%$0 MNov 13, 2026
71Boothbay Fund Management, LLC54,807New0.05%$0 MNov 16, 2026
72Bank Of Nova Scotia49,419New0.04%$0 MNov 13, 2026
73BNP Paribas Financial Markets46,679-74,536 (-61.49%)0.04%$0 MNov 12, 2026
74MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.45,002+4,952 (+12.36%)0.04%$0 MNov 16, 2026
75Alliancebernstein L.P.44,920-4,020 (-8.21%)0.04%$0 MNov 16, 2026
76Osaic Holdings, Inc.44,426+1,311 (+3.04%)0.04%$0 MNov 12, 2026
77XTX Topco Ltd42,612-47,418 (-52.67%)0.04%$0 MNov 16, 2026
78Citigroup Inc40,578-33,536 (-45.25%)0.04%$0 MNov 4, 2026
79MetLife Investment Management, LLC39,509-6,476 (-14.08%)0.04%$0 MNov 16, 2026
80Quadrature Capital Ltd36,794New0.03%$0 MNov 13, 2026
81Barclays PLC36,217+16,223 (+81.14%)0.03%$0 MNov 6, 2026
82Susquehanna International Group, LLP35,095+4,723 (+15.55%)0.03%$0 MNov 16, 2026
83Profund Advisors LLC32,353+12,497 (+62.94%)0.03%$0 MOct 29, 2026
84Ameriflex Group, Inc.32,063-1,535 (-4.57%)0.03%$0 MNov 16, 2026
85Rockefeller Capital Management L.P.30,0000 (0.00%)0.03%$0 MNov 13, 2026
86BCV Asset Management Inc.26,315-50 (-0.19%)0.02%$0 MNov 6, 2026
87Robertson Stephens Wealth Management, LLC25,0000 (0.00%)0.02%$0 MOct 16, 2026
88Keating Financial Advisory Services, Inc.24,9110 (0.00%)0.02%$0 MNov 12, 2026
89Magnetar Financial LLC23,818New0.02%$0 MNov 13, 2026
90Police & Firemen's Retirement System of New Jersey22,9580 (0.00%)0.02%$0 MNov 9, 2026
91Manufacturers Life Insurance Company, The20,998+388 (+1.88%)0.02%$0 MNov 13, 2026
92New York State Common Retirement Fund19,2000 (0.00%)0.02%$0 MNov 17, 2026
93Persistent Asset Partners Ltd17,826+15,046 (+541.22%)0.02%$0 MNov 13, 2026
94Foundations Investment Advisors, LLC15,554New0.01%$0 MNov 12, 2026
95Creative Planning15,319New0.01%$0 MNov 2, 2026
96SBI Securities Co., Ltd.14,965+124 (+0.84%)0.01%$0 MOct 22, 2026
97Voya Investment Management LLC14,8440 (0.00%)0.01%$0 MNov 10, 2026
98Magnolia Capital Advisors LLC14,100-1,000 (-6.62%)0.01%$0 MNov 16, 2026
99Royal Bank Of Canada14,010+1,634 (+13.20%)0.01%$0 MNov 16, 2026
100Prudential Financial Inc13,450+410 (+3.14%)0.01%$0 MNov 16, 2026

All 132 institutional investors, with who bought and sold →

Superinvestors holding Achieve Life Sciences, Inc.

1 of the well-known investors value.today follows, from their newest Form 13F.

Mutual funds holding Achieve Life Sciences, Inc.#

62 funds hold shares worth $98 M (about 13.8% of the company). Since their previous reports 54 added shares and 5 sold, buying $65 M net.
Mutual funds holding Achieve Life Sciences, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.3.11 M$20 M2.8%<0.01%+99%Jun 30, 2026
🇺🇸 Eventide Healthcare & Life Sciences FundEventide Asset Management, LLC2.22 M$14 M2.0%0.81%newJun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors1.99 M$13 M1.8%0.02%newJun 30, 2026
🇺🇸 State Street SPDR S&P Biotech ETFSSGA Funds Management, Inc.1.35 M$9 M1.2%0.08%newJun 30, 2026
🇺🇸 Franklin Biotechnology Discovery FundFranklin Advisers, Inc.1.10 M$7 M1.00%0.61%−30%Jul 31, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.957,389$6 M0.87%<0.01%+64%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC851,832$5 M0.77%0.02%newJul 31, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors731,016$5 M0.66%0.03%newJun 30, 2026
🇺🇸 Franklin Biotechnology Discovery FundFranklin Advisers, Inc.706,649$5 M0.64%0.39%no changeJul 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors261,589$2 M0.24%0.11%+117%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC276,242$1 M0.25%<0.01%−1.5%May 31, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.189,138$1 M0.17%0.02%newJul 31, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC145,507$1 M0.13%0.02%newJun 30, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC103,456$1 M0.09%0.02%newJul 31, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC84,148$1 M0.08%0.01%newJun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC97,174$1 M0.09%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC72,934$0 M0.07%0.03%newJun 30, 2026
🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC67,194$0 M0.06%<0.01%newJul 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC80,161$0 M0.07%<0.01%+5.1%May 31, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation56,300$0 M0.05%0.02%newJun 30, 2026
🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC46,642$0 M0.04%<0.01%+71%Jul 31, 2026
🇺🇸 Direxion Daily S&P Biotech Bull 3X SharesRAFFERTY ASSET MANAGEMENT, LLC45,865$0 M0.04%0.06%newJul 31, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.43,000$0 M0.04%<0.01%no changeJul 31, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.42,235$0 M0.04%<0.01%+58%Jun 30, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.40,160$0 M0.04%0.02%newJun 30, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC37,028$0 M0.03%0.02%newJul 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.33,105$0 M0.03%<0.01%+16%Jun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC37,770$0 M0.03%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC30,577$0 M0.03%<0.01%+66%Jul 31, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC28,131$0 M0.03%0.02%newJun 30, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC26,074$0 M0.02%0.02%newJun 30, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.25,500$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc.24,203$0 M0.02%0.04%−4.5%Jun 30, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC22,114$0 M0.02%0.02%newJun 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC19,040$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC19,040$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC17,463$0 M0.02%0.05%+104%Jun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS17,167$0 M0.02%0.02%newJun 30, 2026
🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC16,088$0 M0.01%0.02%newJun 30, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC13,627$0 M0.01%<0.01%newJul 31, 2026
🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC12,486$0 M0.01%0.02%+54%Jul 31, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.12,219$0 M0.01%0.02%newJun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.11,873$0 M0.01%0.02%newJun 30, 2026
🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC11,732$0 M0.01%0.02%newJun 30, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC10,451$0 M<0.01%0.02%newJun 30, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC9,509$0 M<0.01%0.02%newJun 30, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC9,115$0 M<0.01%0.02%newJul 31, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.8,529$0 M<0.01%<0.01%+60%Jul 31, 2026
🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC7,071$0 M<0.01%0.03%newJun 30, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management7,064$0 M<0.01%0.02%newJun 30, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS6,847$0 M<0.01%0.02%newJul 31, 2026
🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC6,715$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC6,224$0 M<0.01%0.02%newJun 30, 2026
🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC5,335$0 M<0.01%0.02%newJun 30, 2026
🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC3,846$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC3,491$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC2,706$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS2,633$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Avantis Total Equity Markets ETFAmerican Century ETF Trust2,870$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc.1,965$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC1,304$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC976$0 M<0.01%<0.01%−3.1%Jun 30, 2026
🇺🇸 State Street Balanced Index FundSSGA Funds Management, Inc.725$0 M<0.01%<0.01%newJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 63 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Achieve Life Sciences, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$175 K
1 sale, 1 insider
Net, 12 months
-$175 K
open market only
Insiders on file
20
since
$58 K-$1.1 M$0Mar 2024: bought $46 K (2 trades), sold $0 (0 trades)Mar 24Mar 2025: bought $58 K (2 trades), sold $0 (0 trades)MarSep 2025: bought $0 (0 trades), sold $1.1 M (6 trades)SepAug 2026: bought $0 (0 trades), sold $175 K (1 trades)Aug
Bought (open market)Sold (open market)Hover a month for the totals
Achieve Life Sciences, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Richard Alistair StewartDirectorSell-20,626$8.490$175 K208,249Form 4
filed Mark K. OkiChief Financial OfficerOption exercise+168,000——178,000Form 4
filed Richard Alistair StewartChief Executive Officer, DirectorOption exercise+297,500——358,376Form 4
filed Mark K. OkiChief Financial OfficerSell-50,060$2.920$146 K127,940Form 4
filed Richard Alistair StewartChief Executive Officer, DirectorSell-129,501$2.920$378 K228,875Form 4
filed Jerry WanPrincipal Accounting OfficerOption exercise+34,100——46,764Form 4
filed Jaime XinosChief Commercial OfficerOption exercise+69,000——95,286Form 4
filed Thomas Braxton KingDirectorOption exercise+455,000——455,000Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Achieve Life Sciences, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
18.1 M
34.1% of shares · 13.58 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-20 reverse split ; 1-for-10 reverse split

Fails to deliver

  • : 147,962 shares at $7.19
  • : 45,489 shares at $6.85
  • : 155 shares at $6.49
  • : 134 shares at $6.50
  • : 145 shares at $6.51

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Achieve Life Sciences, Inc. scorecard#

Passes 1 of the 12 checks that could be worked out. Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation0 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median36.8×Price to book 36.8× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-6.2%Free cash flow is -6.2% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-1.25 vs -1.24Diluted EPS -1.25 in fiscal 2025 against -1.24 the year before (report's currency).
    • ✗Net income higher than five years earlier-$55 M-$55 M in fiscal 2025 against -$15 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$55 MNet income -$55 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-257.7%-257.7% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities4.4×Current ratio 4.39 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year35.9%Diluted shares up 35.9% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Achieve Life Sciences, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Achieve Life Sciences, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue——————00——
Research and development—231630246.99.75.93.10.3r
General and administrative—1611119.17.96.96.93.51.4r
Total costs and expenses55392741331517136.61.7r
Interest and finance income1.52.40.80.20.00.10.20.20.00.2
Interest expense and finance costs0.82.22.91.8——————
Other non-operating income (expense)0.2−0.8−2.6−1.6−0.10.00.10.1−7.0−0.0r
Income before tax−55−40−30−42−33−15−16−13−14−1.7
Income tax—————————0
Net income including minority interests−55−40−30−42−33−15−16−13−11−1.2
Net income attributable to shareholders−55−40−30−42−33−15−16−13−11−1.2r
Earnings per share, basic-1.25-1.24-1.50-4.00-4.08-5.42-39.76r-72.29r-22.07r-581.25r
Earnings per share, diluted-1.25-1.24-1.50-4.00-4.08-5.42-39.76r-72.29r-22.07r-581.25r
Shares, weighted average (basic)443220r118.12.7————
Shares, weighted average (diluted)443220r118.12.70.4r0.2r0.5r0.0r
Balance sheet
Cash and cash equivalents211316254336179.55.30.0r
Short-term investments1522—————5.1—10
Receivables——————0.00.00.00.5
Other current assets—2.11.32.51.41.10.7r0.9—1.0
Current assets40361727453717165.90.0r
Property, plant and equipment0.00.00.00.00.00.00.10.00.10.3
Right-of-use (leased) assets0.10.10.10.1r0.10.10.3———
Goodwill1.01.01.01.01.01.01.01.01.01.0
Other intangible assets0.81.01.21.41.61.92.12.32.52.8
Total assets42391930484021199.93.8r
Accounts payable—2.00.61.70.80.30.90.10.20.1r
Current liabilities9.16.721224.62.92.93.32.03.1r
Lease liabilities (non-current)0.00.10.00.10.00.10.20.0——
Total liabilities20182122193.03.03.32.03.2r
Retained earnings−260−206−166−136−94−60−46−25−13−2.1r
Shareholders' equity2221−1.48.3283718167.90.6r
Total liabilities and equity42391930484021199.93.8r
Shares outstanding533521189.56.11.5r6.71.2r0.0r
Cash-flow statement
Depreciation and amortization0.20.20.20.20.30.3————
Share-based compensation8.85.33.43.32.21.31.20.90.31.6
Cash from operating activities−49−30−24−38r−29−13−15−11−9.1−0.2r
Capital expenditure−0.0—−0.0——−0.0−0.1−0.0—−0.0
Cash from investing activities6.1−22−0.0——−0.05.0−5.11311
Shares issued————————0.1—
Cash from financing activities52491519r373317202.00.2r
Exchange-rate effect on cash————————−0.0—
Change in cash8.2−2.8−9.2−187.2197.14.05.5−0.1r
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Executive pay at Achieve Life Sciences, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$1.4 M
Richard Stewart
Other top executives, average
$964 K
the CEO earned 1.4× this
$100 invested is now
$203
Achieve Life Sciences, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Richard Stewart$1.4 M$1.5 M$964 K$203
2024Andrew D. Goldberg$2.5 M$2.2 M$1.1 M$144
2023John Bencich$1.7 M$1.6 M$1.3 M$168

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Achieve Life Sciences, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 9 · Material agreement 4 · New debt 1 · Unregistered share sale 2 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 10

Achieve Life Sciences, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Directors and officers8-K
Results announced8-K
Bylaws or fiscal year changedShareholder vote8-K
Directors and officers8-K
Directors and officersResults announced8-K
Directors and officersMaterial agreementUnregistered share sale8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Results announced8-K
Material agreement8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Results announced8-K
Material agreement8-K
Directors and officers8-K
Results announced8-K
Material agreementNew debtUnregistered share sale8-K
Shareholder vote8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026

Acquisitions and funding#

1 private funding rounds before listing

Private share sales · funding history

Private share sales of Achieve Life Sciences, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2009$10 MNo. 1$10 to $50 million1equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Layoffs at Achieve Life Sciences, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
43
2007–2016
Latest
—
2016-11-14
Achieve Life Sciences, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2016·11·······16··27
2008············—
2007··········16·16
Achieve Life Sciences, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
Not statedRestructuring planSEC 8-KCompany-wide planFiling
16 people (55% of workforce)Restructuring planSEC 8-K“As part of this restructuring, the Company will eliminate 16 positions, representing approximately 55% of the Company’s workforce.”Filing
11 people (27% of workforce)Restructuring planSEC 8-K“(the “Company”) committed to a plan to reduce operating expenses, which included a workforce reduction of 11 employees, representing approximately 27% of the Company’s employees pr…”Filing
49% of workforceRestructuring planSEC 8-K“The Company will reduce workforce by approximately 49%.”Filing
Not statedRestructuring planSEC 8-KCompany-wide planFiling
16 peopleRestructuring planSEC 8-K“(the “Company”) implemented a reduction in workforce (the “Reduction in Workforce”) pursuant to which the Company’s workforce was reduced by 16 positions, or approximately 25%, lea…”Filing

Source: State WARN notices and SEC 8-K item 2.05

Discuss Achieve Life Sciences, Inc.#

2 automatic updates and 0 member comments. Sign in to comment and react.

  • Results announced on 10 November 2026automatic update · Nov 10, 2026

    Achieve Life Sciences, Inc. announced results on 10 November 2026 (SEC Form 8-K, item 2.02). For the quarter ended 30 September 2026: a net loss of $12 million.

  • Mutual funds: 62 funds hold $98 millionautomatic update · Jul 31, 2026

    62 mutual funds in 1 country hold shares of Achieve Life Sciences, Inc. worth $98 million, about 13.8% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 54 funds added shares and 5 sold; on balance they bought $65 million. Share splits are not counted as trading.

How Achieve Life Sciences, Inc. compares in Biotechnology

  • Market cap$791 M · higher than 64% of 726
  • Price / book36.8× · lower than 5% of 534
  • FCF yield-6.3% · higher than 67% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Achieve Life Sciences, Inc.🇺🇸$791 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Achieve Life Sciences, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Achieve Life Sciences, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Achieve Life Sciences, Inc.? Suggest a correction